{
    "organizations": [],
    "uuid": "f3ac3919ae758bbc83426cd5c346197c0b9da5ef",
    "author": "",
    "url": "https://www.reuters.com/article/brief-obseva-reports-q4-loss-per-share-0/brief-obseva-reports-q4-loss-per-share-0-48-idUSASB0C9P4",
    "ord_in_thread": 0,
    "title": "BRIEF-ObsEva Reports Q4 Loss Per Share $0.48",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 9 (Reuters) - Obseva Sa:\n* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q4 LOSS PER SHARE $0.48 * Q4 EARNINGS PER SHARE VIEW $-0.56 â€” THOMSON REUTERS I/B/E/S\n* EXPECTS 12 WEEK RESULTS FROM PHASE 2B EDELWEISS CLINICAL TRIAL OF OBE2109 FOR TREATMENT OF ENDOMETRIOSIS, IN MID-2018\n* EXPECTS INITIAL EFFICACY RESULTS FROM PHASE 2A PROLONG CLINICAL TRIAL OF OBE022 IN PRE-TERM LABOR IN LATE 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-09T15:54:00.000+02:00",
    "crawled": "2018-03-09T16:12:31.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "obseva",
        "sa",
        "obseva",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "expects",
        "week",
        "result",
        "phase",
        "2b",
        "edelweiss",
        "clinical",
        "trial",
        "obe2109",
        "treatment",
        "endometriosis",
        "expects",
        "initial",
        "efficacy",
        "result",
        "phase",
        "2a",
        "prolong",
        "clinical",
        "trial",
        "obe022",
        "labor",
        "late",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}